Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments Momentum Movers

Inovio Pharmaceuticals (INO) PT Raised to $14 at Aegis CapitalMay 25, 2017 8:15 AM UPDATE: Inovio Pharmaceuticals (INO) PT Raised to $12 at Maxim Group; 'A Step Closer to HIV Vaccine, PENNVAX-GP Demonstrates High Immune Response Rates'May 24, 2017 2:29 PM Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical StudyMay 24, 2017 8:01 AM